Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Orion

99.15 EUR-0.80 %3.11. klo 18.29
14,528 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-0.80 %
+22.71 %
+25.11 %
+44.32 %
+55.77 %
+63.75 %
+168.84 %
+164.05 %
+782.90 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
13.99B EUR
Turnover
10.77M EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Reduce
Target price
Updated
29.10.2026
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Jefferies upgrades Orion stock on Nubeqa patent outlook Jefferies upgraded Orion Oyj (ORNBV:FH) (OTC:ORINY) to Buy from Hold and raised its price target to EUR115.00 from EUR77.00. “Analyysitalon mukaan nykyinen arvostus olettaa, että Nubeqan markkinaeksklusiivisuus päättyy vuonna...
10/26/2026, 6:44 AM
by Dissidentti
25
Hi, very good and relevant questions for the investment case! I think there could already be some minor impact in 2027, but in terms of scale it would still be small enough to be overshadowed by the overall Nubeqa picture. So, I took a bit of a shortcut with my wording. Reasons why...
10/29/2026, 11:18 AM
by Antti Siltanen
11
That slide shows royalties. Nubeqa and then MSD’s drug. For Nubeqa, it doesn’t stay at 20% for sales over 3 billion, but rises to 25%. And manufacturing costs are also mentioned in calculating the margin.
10/28/2026, 12:43 PM
by Vino Pino
9
YTD over 50% and churning out results. Whether too much was already priced in should become clear this afternoon. Inderes Orion-konsernin osavuosikatsaus tammi–syyskuu 2026: Vahva taloudellinen... ORION OYJ OSAVUOSIKATSAUS 1–9/2026 28.10.2026 klo 12:00 Orion-konsernin osavuosikatsaus...
10/28/2026, 10:01 AM
by Gwertheney
7
Here are Antti’s comments regarding this recent news from Orion On Saturday, Orion announced strong interim analysis results from the Phase 3 DASL-HiCaP study. Adding darolutamide (Nubeqa) to standard of care reduced the risk of metastasis or death by 58% in patients with early-stage...
10/26/2026, 6:10 AM
by Sijoittaja-alokas
7
Orion’s CEO Liisa Hurme talked with Antti about the Q3 results and other recent topics Topics: (00:00) Introduction (00:11) ”An excellent quarter” (00:23) Nubeqa behind the strong result (01:25) Organizational change (04:07) Manufacturing of Nubeqa’s active ingredient (05:08) DASL...
10/28/2026, 5:57 PM
by Sijoittaja-alokas
5
Here is a company report on Orion by Siltanen following Q3 :)\n\n> Orion’s Q3 was once again strong. Earnings clearly beat our estimates, and revenue was in line with expectations. The earnings beat was driven by stronger-than-expected growth in high-margin Nubeqa royalties. We are...
10/29/2026, 9:27 AM
by Sijoittaja-alokas
4
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.2.
2027

Annual report '26

23.3.
2027

General meeting '27

22.4.
2027

Interim report Q1'27

Orion, Webcast, Q3'26
Webcast28.10.2026 klo 14.00

Orion, Webcast, Q3'26

Orion
Regulatory press release28.10.2026 klo 12.00

Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline

Orion
Regulatory press release26.10.2026 klo 13.00

Changes in Orion Group’s Executive Team as of 1 January 2027

Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release24.10.2026 klo 09.35

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Orion
Regulatory press release20.10.2026 klo 20.20

Inside information: Orion upgrades full-year outlook for 2026

Orion
Press release14.10.2026 klo 09.00

Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026

Orion
Regulatory press release07.10.2026 klo 09.00

125,000 Orion Corporation A shares converted into B shares

Orion
Press release06.10.2026 klo 09.00

Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market

Orion
Press release05.10.2026 klo 15.00

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing

Orion
Regulatory press release30.09.2026 klo 09.05

Orion Corporation completed share acquisitions

Orion
Regulatory press release30.09.2026 klo 09.00

Orion Corporation: Acquisition of own shares during week 40, 2026

Orion
Regulatory press release25.09.2026 klo 19.00

Orion Corporation: Acquisition of own shares during week 39, 2026

Orion
Regulatory press release18.09.2026 klo 19.00

Orion Corporation: Acquisition of own shares during week 38, 2026

Orion
Regulatory press release11.09.2026 klo 19.00

Orion Corporation: Acquisition of own shares during week 37, 2026

Orion
Regulatory press release04.09.2026 klo 19.00

Orion Corporation: Acquisition of own shares during week 36, 2026

Orion
Regulatory press release04.09.2026 klo 09.00

102,000 Orion Corporation A shares converted into B shares

Orion
Regulatory press release27.08.2026 klo 13.00

Orion Corporation to commence acquisition of own shares for its share-based incentive plans

Orion
Regulatory press release10.08.2026 klo 14.05

Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint

Orion
Orion, Webcast, Q2'26
Webcast17.07.2026 klo 14.00

Orion, Webcast, Q2'26

Orion
Regulatory press release17.07.2026 klo 12.00

Orion Group Half-Year Financial Report January–June 2026

Orion